Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
Levy A, Khalifa J, Martin E, Botticella A, Quevrin C, Lavaud P, Aldea M, Besse B, Planchard D, Barlesi F, Deutsch E, Massabeau C, Doyen J, Le Péchoux C. Levy A, et al. Among authors: martin e. Clin Transl Radiat Oncol. 2023 May 3;41:100637. doi: 10.1016/j.ctro.2023.100637. eCollection 2023 Jul. Clin Transl Radiat Oncol. 2023. PMID: 37206411 Free PMC article.
Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group.
Fourquet J, Sunyach MP, Vilotte F, Le Péchoux C, Ranchère-Vince D, Bonvalot S, Coindre JM, Terrier P, Meeus P, Helfre S, Martin E, Vogin G, Biau J, Kao W, Noel G, Ducassou A, Llacer-Moscardo C, Stoeckle E, Penel N, Sargos P. Fourquet J, et al. Among authors: martin e. Radiother Oncol. 2016 Jul;120(1):156-62. doi: 10.1016/j.radonc.2016.04.037. Epub 2016 May 17. Radiother Oncol. 2016. PMID: 27207359
Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).
Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, Hapdey S, Pallardy A, Mahé MA, Lacombe M, Boisselier P, Guillemard S, Olivier P, Beckendorf V, Salem N, Charrier N, Chajon E, Devillers A, Aide N, Danhier S, Denis F, Muratet JP, Martin E, Riedinger AB, Kolesnikov-Gauthier H, Dansin E, Massabeau C, Courbon F, Farcy Jacquet MP, Kotzki PO, Houzard C, Mornex F, Vervueren L, Paumier A, Fernandez P, Salaun M, Dubray B. Vera P, et al. Among authors: martin e. J Nucl Med. 2017 Jul;58(7):1045-1053. doi: 10.2967/jnumed.116.188367. Epub 2017 Mar 2. J Nucl Med. 2017. PMID: 28254869 Free article. Clinical Trial.
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A, Rio E, Bera G, Ruffier A, Quivrin M, Chasseray M, Latorzeff I, Martin E, Guimas V, Pommier P, Leroy T, Ronchin P, Lepinoy A, Grand A, Cartier L, Didas O, Denis F, Libois V, Blanc-Lapierre A, Supiot S. Rogé M, et al. Among authors: martin e. Clin Transl Radiat Oncol. 2023 Mar 8;40:100613. doi: 10.1016/j.ctro.2023.100613. eCollection 2023 May. Clin Transl Radiat Oncol. 2023. PMID: 36968576 Free PMC article.
Immune changes in hilar tumor draining lymph nodes following node sparing neoadjuvant chemoradiotherapy of localized cN0 non-small cell lung cancer.
Khalifa J, Thébault N, Scarlata CM, Norkowski E, Massabeau C, Brouchet L, Peries Bataille S, Casaroli C, Vaz L, Valle C, Sarot E, Saint-Laurent N, Martin E, Pages PB, Millière A, Mazières J, Cohen-Jonathan Moyal E, Lauzéral-Vizcaïno F, Ayyoub M. Khalifa J, et al. Among authors: martin e. Front Oncol. 2023 Nov 22;13:1269166. doi: 10.3389/fonc.2023.1269166. eCollection 2023. Front Oncol. 2023. PMID: 38074683 Free PMC article.
Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma-a French DELPHI Consensus Initiative.
Basse C, Khalifa J, Thillays F, Le Pechoux C, Maury JM, Bonte PE, Coutte A, Pourel N, Bourbonne V, Pradier O, Belliere A, Le Tinier F, Deberne M, Tanguy R, Denis F, Padovani L, Zaccariotto A, Molina T, Chalabreysse L, Brioude G, Delatour B, Faivre JC, Cao K, Giraud P, Riet FG, Thureau S, Antoni D, Massabeau C, Keller A, Bonnet E, Lerouge D, Martin E, Girard N, Botticella A. Basse C, et al. Among authors: martin e. J Thorac Oncol. 2024 Jul;19(7):1095-1107. doi: 10.1016/j.jtho.2024.04.003. Epub 2024 Apr 10. J Thorac Oncol. 2024. PMID: 38608932
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P. Vera P, et al. Among authors: martin e. Lancet Oncol. 2024 Sep;25(9):1176-1187. doi: 10.1016/S1470-2045(24)00320-6. Epub 2024 Aug 9. Lancet Oncol. 2024. PMID: 39134086 Clinical Trial.
6,335 results